Dengue Vaccine Development
GSID’s expertise in clinical and product development has been utilized by the Pediatric Dengue Vaccine Initiative (PDVI), a program of the International Vaccine Institute in Seoul, Korea. Beginning in 2008, we evaluated candidate vaccines, their respective developers and potential manufacturing partners around the world. Our evaluations of development partners provided PDVI with the necessary input to further the advancement of evaluating dengue vaccines in large-scale trials.
In December 2010, Dr. Don Francis co-authored an Occasional Paper for the International Vaccine Institute on "The Manufacture and Supply of Dengue Vaccine." A copy of the paper can be found here.
In 2011, the International Vaccine Institute announced that they had received funding from the Bill & Melinda Gates Foundation for the creation of the Dengue Vaccine Iniative (DVI), which was established to build on the work of the Pediatric Dengue Vaccine Initiative (PDVI) and to further awareness of the need to support the development and use of dengue vaccines.
GSID has been working directly with the Butantan Institute (Sao Paolo, Brazil) on their dengue vaccine development program. Butantan licensed a tetravalent dengue vaccine from the NIH, and they are currently building a manufacturing plant and designing clinical trials to begin 2011-2012.
About Dengue
Dengue fever is a mosquito-borne disease, primarily of children, and prevalent in tropical countries around the world. Dengue fever has severe consequences of hemorrhagic fever and dengue shock and results in substantial morbidity and mortality. There is currently no vaccine available for dengue, although a number of vaccine candidates are in various stages of development. For more information please see:
The Dengue Vaccine development program has been supported through funding from the International Vaccine Institute and the Butantan Institute.
